Research status and progress of hypoxia-inducible factor on the regulation of diabetic retinopathy
10.3760/cma.j.cn511434-20200609-00268
- VernacularTitle:缺氧诱导因子对糖尿病视网膜病变调控作用的研究现状与进展
- Author:
Mengxia HE
1
;
Jie XIE
;
Qianli MENG
Author Information
1. 广东省人民医院眼科 广东省眼病防治研究所 广东省医学科学院，广州 510080
- Keywords:
Diabetic retinopathy;
Hypoxia-inducible factor 1, alpha subunit;
Vascular endothelial growth factors;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2021;37(8):661-664
- CountryChina
- Language:Chinese
-
Abstract:
The intervention therapy targeting vascular endothelial growth factor (VEGF) has become a specific and effective method for the treatment of diabetic retinopathy (DR). However, some patients did not respond or responded poorly to anti-VEGF therapy, and its effects of eliminating edema and improving vision appear to be unstable in the same patient. Hypoxia-inducible factor-1α (HIF-1α), an important upstream transcriptional regulator of VEGF, is an oxygen concentration-sensitive protein expressed in tissues under hypoxia. It can simultaneously target many downstream target genes except VEGF, such as placental growth factor and angiopoietin-like protein 4, to cause blood-retinal barrier damage and neovascularization, and thus participate in various pathological changes of DR to promote the occurrence and development of DR. Therefore, direct intervention of HIF-1α or targeting one or more downstream target genes regulated by HIF-1α to treat DR may have better efficacy. In the future, the development of effective and safe HIF inhibitors or anti-VEGF with HIF-1α other target gene inhibitors may have broader clinical application prospects.
